Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 from Sancho et al.

Published byLuiz Felipe Carneiro da Costa Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 from Sancho et al."— Presentation transcript:

1 Targeting cancer stem cells through inhibition of mitochondrial function
Figure 2 from Sancho et al. British Journal of Cancer Advance Online Publication 24 May 2016 doi: /bjc Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2016 Cancer Research UK.

Download ppt "Figure 2 from Sancho et al."

Similar presentations

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Advanced Cancer Topics Journal Review 4/16/2009 AD.
Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.
Progress in Cancer Therapy Following Developments in Biopharma

Progress in Cancer Therapy Following Developments in Biopharma
Schema for a human microbiome study

Schema for a human microbiome study
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Inhibitor of MAP kinase activation blocks colon cancer growth

Inhibitor of MAP kinase activation blocks colon cancer growth
Advances in Specific Immunotherapy for Prostate Cancer

Advances in Specific Immunotherapy for Prostate Cancer
Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.
Figure 7 Clinical options for HCC therapy

Figure 7 Clinical options for HCC therapy
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Focus on breast cancer Cancer Cell

Focus on breast cancer Cancer Cell
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 4 Possible combination therapies CDK4/6 inhibitors
The PI3K/Akt signalling and its activation in cancer

The PI3K/Akt signalling and its activation in cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
The hallmarks of adenovirus infection

The hallmarks of adenovirus infection
The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.
Figure 1 Targets for monoclonal antibodies in B-cell lineages

Figure 1 Targets for monoclonal antibodies in B-cell lineages

Similar presentations

Ads by Google